Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lixte Biotech Hlds (LIXT)

Lixte Biotech Hlds (LIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,376
  • Shares Outstanding, K 2,249
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,090 K
  • 60-Month Beta -0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LIXT with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +7.96%
on 05/15/24
3.40 -28.56%
on 04/25/24
-0.85 (-25.95%)
since 04/24/24
3-Month
1.90 +27.84%
on 02/26/24
4.40 -44.80%
on 03/27/24
+0.21 (+9.41%)
since 02/23/24
52-Week
1.58 +53.73%
on 09/19/23
9.50 -74.43%
on 07/17/23
-4.56 (-65.25%)
since 05/24/23

Most Recent Stories

More News
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on...

LIXT : 2.43 (+1.63%)
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical...

LIXT : 2.43 (+1.63%)
LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing...

LIXT : 2.43 (+1.63%)
WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

WestPark Capital, Inc., a full-services investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT),...

LIXT : 2.43 (+1.63%)
LIXT Stock Gets 200%+ Lift, Don’t Get Caught on the Way Down

Hold off on LIXT stock for now while its products remain in the early trial stages

LIXT : 2.43 (+1.63%)
Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today

Microcap biotech stocks are skyrocketing today. Here are the names investors need to know.

SBFM : 0.7550 (+1.75%)
PTE : 0.2410 (-0.82%)
QLGN : 0.3050 (+6.09%)
LIXT : 2.43 (+1.63%)
ATNM : 8.50 (+0.95%)
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing...

LIXT : 2.43 (+1.63%)
Why Is Lixte Biotechnology (LIXT) Stock Up Today?

LIXT performed well against cancer in recent trials

TSLA : 179.24 (+3.17%)
LIXT : 2.43 (+1.63%)
OCGN : 1.7500 (-1.69%)
LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on...

LIXT : 2.43 (+1.63%)
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with mutations reducing PP2A activity in their...

LIXT : 2.43 (+1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Lixte Biotechnology Holdings Inc. is a drug discovery company which uses biomarker technology to identify enzyme targets associated with serious common diseases. The company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents...

See More

Key Turning Points

3rd Resistance Point 2.63
2nd Resistance Point 2.56
1st Resistance Point 2.49
Last Price 2.43
1st Support Level 2.36
2nd Support Level 2.29
3rd Support Level 2.22

See More

52-Week High 9.50
Fibonacci 61.8% 6.47
Fibonacci 50% 5.54
Fibonacci 38.2% 4.61
Last Price 2.43
52-Week Low 1.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar